Simplify Logo

Full-Time

Vice President

Business Development

Confirmed live in the last 24 hours

Absci

Absci

51-200 employees

Biotech company specializing in protein production

Biotechnology

Compensation Overview

$270k - $330kAnnually

+ Performance-based bonus + Equity package

Senior

Remote in USA

Category
Business Development
Business & Strategy
Requirements
  • Experience working with CxO level executives to influence partnering decisions
  • 6+ years of relevant biotech/pharma industry experience in a corporate strategy or business development role and with a strong background in science.
  • Knowledge of next-generation biologics discovery, development and licensing processes.
  • Demonstrated track records of extensive network of relevant industry contacts.
  • Demonstrated track record of negotiating and closing a wide range of business agreements including partnerships, joint ventures, licensing agreements, co-promotions, strategic alliances and other types of corporate ventures.
  • Ability to prioritize multiple stakeholders and projects
  • Experience working across different R&D and delivery functions within an organization to meet customer demands.
  • Entrepreneurial mentality that is hands-on, results oriented, and resourceful.
  • Ability to travel up to 25% of the time
  • Excellent presentation, communication and interpersonal skills.
  • PhD or Masters Degree in a science-related field or MBA (Nice to have)
  • Business development experience working in big pharma, biopharma or biotech environments (Nice to have)
Responsibilities
  • Identify and build a robust business development pipeline of prospective pharmaceutical company and biotech company partners in the biologics area.
  • Lead business development efforts, from deal sourcing to deal close, with strong focus on execution, counterparty diligence, and evaluation of deal merit in the context of the company’s portfolio of partnerships.
  • Develop and negotiate term sheets for a variety of deal types, including drug discovery partnerships, target discovery partnerships, therapeutic asset partnerships, therapeutic asset sales, and co-development.
  • Develop strategic relationships and networks for identifying business development opportunities as well as for staying abreast of industry technology and deal-making trends.
  • Evaluate risks in potential transactions with an understanding of valuation and deal structuring. Take into account the end goal of all parties, and actively participate in due diligence, including legal, financial, commercial, and business implications.
  • Work collaboratively to lead discussions and align internal and external stakeholders.
  • Articulate and communicate Absci’s mission, vision, values, business and technical vision to potential biotech clients and partners.
  • Set annual and long-term business-performance objectives and lead their delivery for a strategic function or group of businesses; manage and report on performance; hold direct reports accountable for achievement of business plans, and take corrective action where necessary to ensure achievement, balancing the need to deliver short-term business objectives with the longer-term delivery of stakeholder value.
  • Evaluate current capabilities, identify gaps based on market feedback, and contribute to strategic R&D prioritization discussions.

AbSci focuses on improving protein expression and biomanufacturing in the biotech industry. Its main product is an advanced protein expression platform that uses a semi-oxidizing cytoplasm and a dual inducible promoter system, allowing for better control over protein production rates. This results in higher quality and more efficient drug manufacturing. A key feature of AbSci's offerings is SoluPure, a method that simplifies protein purification without chromatography, speeding up the production process and reducing costs. AbSci's workflow can create cell lines that produce active proteins in as little as three months, which is much faster than traditional methods. Unlike its competitors, AbSci aims to replace older mammalian expression systems with its more efficient solutions. The company's goal is to enhance drug discovery and manufacturing processes for pharmaceutical and biotech companies, ultimately transforming the production of biologics.

Company Stage

IPO

Total Funding

$324.3M

Headquarters

Vancouver, Washington

Founded

2011

Growth & Insights
Headcount

6 month growth

2%

1 year growth

-2%

2 year growth

-3%
Simplify Jobs

Simplify's Take

What believers are saying

  • AbSci's recent $86M public stock offering and strategic partnerships, such as with AstraZeneca, highlight strong financial backing and growth potential.
  • The company's ability to generate cell lines producing active protein products in as little as three months accelerates drug development timelines, offering significant time and cost savings.
  • AbSci's collaboration with PrecisionLife to develop an AI-enabled drug pipeline demonstrates their commitment to innovation and addressing unmet medical needs.

What critics are saying

  • The biotech industry is highly competitive, and AbSci must continuously innovate to maintain its edge over established and emerging competitors.
  • Relying heavily on strategic partnerships and collaborations could pose risks if these relationships falter or fail to deliver expected outcomes.

What makes Absci unique

  • AbSci's SoluPure technology offers a chromatography-free purification method, significantly reducing bottlenecks in protein production compared to traditional techniques.
  • Their advanced protein expression platform with a semi-oxidizing cytoplasm and dual inducible promoter system allows for precise control over protein production rates, setting them apart from competitors.
  • AbSci's integration of generative AI in drug discovery and biomanufacturing positions them uniquely in the biotech industry, combining cutting-edge technology with traditional biopharmaceutical processes.

Help us improve and share your feedback! Did you find this helpful?